2020
DOI: 10.1007/s40620-020-00744-x
|View full text |Cite
|
Sign up to set email alerts
|

Setting the clock back: new hope for dialysis patients. Sodium thiosulphate and the regression of vascular calcifications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 8 publications
0
3
0
Order By: Relevance
“…Sodium thiosulfate (STS) has been suggested to be effective for calciphylaxis in dialysis patients, although the results of previous studies have been inconsistent [ 11 , 12 ]. Several studies have demonstrated that STS has vasodilatory and antioxidant effects and can chelate calcium deposits to form soluble calcium thiosulfate complexes, suggesting that STS may also be effective in attenuating the progression of CAC [ 13–16 ]. However, clinical studies evaluating the influence of intravenous STS on CAC progression in dialysis patients are still limited, generally with small sample sizes and inconsistent results [ 17–25 ].…”
Section: Introductionmentioning
confidence: 99%
“…Sodium thiosulfate (STS) has been suggested to be effective for calciphylaxis in dialysis patients, although the results of previous studies have been inconsistent [ 11 , 12 ]. Several studies have demonstrated that STS has vasodilatory and antioxidant effects and can chelate calcium deposits to form soluble calcium thiosulfate complexes, suggesting that STS may also be effective in attenuating the progression of CAC [ 13–16 ]. However, clinical studies evaluating the influence of intravenous STS on CAC progression in dialysis patients are still limited, generally with small sample sizes and inconsistent results [ 17–25 ].…”
Section: Introductionmentioning
confidence: 99%
“…Sodium thiosulfate alleviated the calcification progress in the iliac arteries and heart valves but failed to alleviate the abdominal aortic calcification (AAC) in patients with end-stage renal disease in a small double-blind, randomized, placebo-controlled study ( 6 ). Large-scale randomized controlled trials are still needed to confirm the potential of sodium thiosulfate to alleviate calcification ( 7 ). Thus, it is of great significance to explore the risk factors and prevent VC ( 8 10 ).…”
Section: Introductionmentioning
confidence: 99%
“…In a small randomized controlled study, sodium thiosulfate failed to hinder the progress of abdominal aortic calcification progress, but it positively affected calcification progress in iliac arteries and heart valves, along with several other cardiovascular functional parameters (9). Large-scale randomized controlled trials are necessary to contribute to support the use of and to gain recognition for sodium thiosulfate (10). Raggi et al found that SNF472 can significantly attenuated the progression of coronary artery calcium and aortic valve calcification in patients with end-stage kidney disease receiving hemodialysis in addition to standard care (8).…”
Section: Introductionmentioning
confidence: 99%